Myriad Genetics News

Myriad Genetics Is Maintained at Underperform by B of A Securities

Dow JonesDec 13 11:25 ET · Ratings

BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Cuts Target Price to $13

Moomoo NewsDec 13 08:33 ET · Ratings

Top Premarket Decliners

MT NewswiresDec 12 07:51 ET

Express News | Myriad Genetics Inc : Jefferies Cuts Target Price to $13 From $15

ReutersDec 12 01:47 ET

Reported Earlier, Myriad Genetics Engages Unitedhealthcare On Pharmacogenetic Testing Policy, Seeks Continued Access To Genesight In 2025

BenzingaDec 11 02:35 ET

Myriad Genetics Talks With UnitedHealthcare on Insurance Exclusion Might Extend Into 2025

WSJDec 10 19:01 ET

Myriad Genetics: During 3Q Earnings Call Provided Estimate of 2024 Fincl Impact of UNH's Updated Medical Policy, Myriad Reaffirms Estimate >MYGN

Dow JonesDec 10 18:37 ET

Myriad Genetics: Desire Resolution Ahead of Yr-End, But Discussions May Extend Into Early 2025 >MYGN

Dow JonesDec 10 18:37 ET

Myriad Genetics: Engaged in Dialogue With UNH Regarding Clinical Evidence Supporting Myriad's Proprietary and Clinically Differentiated Mental Health Medication Test GeneSight >MYGN

Dow JonesDec 10 18:37 ET

Myriad Genetics Engages With UnitedHealthcare on Access to GeneSight Test Following Policy Update

Quiver QuantitativeDec 10 18:30 ET

Express News | Myriad Genetics Provides Update on Discussions With Unitedhealthcare Regarding Medical Policy for Pharmacogenetic Testing

ReutersDec 10 18:26 ET

Myriad Genetics Provides Update on Discussions With UnitedHealthcare Regarding Medical Policy for Pharmacogenetic Testing

GlobeNewswireDec 10 18:26 ET

Express News | Myriad Genetics : Approved an Increase in Size of Board From Eight to Nine Members

ReutersDec 10 16:14 ET

Press Release: Myriad Genetics Expands Board of Directors With Election of Mark S. Davis as New Board Member

Dow JonesDec 10 16:05 ET

Express News | Myriad Genetics Expands Board of Directors With Election of Mark S. Davis as New Board Member

ReutersDec 10 16:05 ET

Myriad Genetics Initiated at Neutral by UBS

Dow JonesDec 10 08:01 ET · Ratings

Express News | Myriad Genetics’ Portfolio Elevated by Updated Nccn Prostate Cancer Guidelines

ReutersDec 10 08:00 ET

Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

GlobeNewswireDec 10 08:00 ET

UBS Initiates Myriad Genetics(MYGN.US) With Hold Rating, Announces Target Price $18

Moomoo NewsDec 10 05:33 ET · Ratings

Cautious Hold: Myriad Genetics Faces Growth Uncertainty Amid Reimbursement Challenges

TipRanksDec 10 05:25 ET · Ratings